This reflects the state of play as of early 2026: States that cover GLP-1s for obesity treatment (fee-for-service): Arkansas, Colorado, Connecticut, Delaware, Illinois, Louisiana, Massachusetts, Minnesota, New Mexico, New York, Oregon, Virginia, Washington approximately 13 states total as of January 2026
Providers increasingly recommend baseline kidney function tests, thyroid screening, and metabolic panels before GLP-1 initiation
Complete information on authors, methodology and conflicts of interest is available in the published paper
Glucagon-Like Peptide-1: A Multi-Faceted Anti-Inflammatory Agent
instead, it plumps them up